



Title: Practical considerations when using emicizumab in patients with Haemophilia A with and without FVIII inhibitors

Objective: An educational session to learn from expert haematologists who have extensive clinical experience in Haemophilia A, as they share their management of patients and considerations when using Hemlibra (emicizumab) in a variety of patient types. Their expertise will support the wider APAC community to enhance medical knowledge, optimize clinical decisions and explore practical considerations in the quality treatment of Hemlibra (emicizumab) in patients with Haemophilia A.

Moderator and Panelists:

- **Associate Professor Doctor Darintr Sosothikul (Moderator)**
Paediatric Haematologist
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- **Professor Dr. Naresh Gupta**
Adult Haematologist
MAMC & Lok Nayak Hospital, New Delhi, India
- **Clin A/Professor Joyce Lam**
Paediatric Haematologist
KK Women's and Children's Hospital, Singapore
- **Professor Huyen Tran**
Adult Haematologist
The Alfred Hospital, Melbourne, Australia

Proposed Agenda:

Time	Agenda
13:00 - 13:05	Welcome and Introduction
13:05 - 13:15	Haemophilia Treatment: APAC Perspective
13:15 - 13:45	Panel Discussion Topics: <ul style="list-style-type: none">• Management of paediatrics Haemophilia A patients• Management of adult Haemophilia A patients: Cardiovascular disease, going through surgery• Non-factor replacement therapy is a risk factor for inhibitor development?• Management of breakthrough bleeds in patients with and without inhibitors being prophylaxis with non-factor
13:45 - 14:00	Q&A